UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number 001-35560

Issuer:  ImmunoCellular Therapeutics, Ltd.
Exchange:  NYSE AMERICAN LLC
(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)
Address:  21900 Burbank Boulevard 3rd Floor
Woodland HIlls,
CALIFORNIA
91367
Telephone number: 
(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)
Common Stock
(Description of class of securities)
Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:
o  17 CFR 240.12d2-2(a)(1)
o  17 CFR 240.12d2-2(a)(2)
o  17 CFR 240.12d2-2(a)(3)
o  17 CFR 240.12d2-2(a)(4)
x   Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. 1
o   Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.
Pursuant to the requirements for the Securities Exchange Act of 1934, NYSE AMERICAN LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.
2018-10-18 By Victoria Paper Senior Analyst
Date Name Title
1 Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.

NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES

NYSE American LLC (the 'Exchange' or 'NYSE American') hereby notifies the Securities and Exchange Commission ('SEC') of its intention to remove the entire class of Common Stock (the ‘Common Stock’), and Warrants to purchase Common Stock $0.0001 par value per share (Expiring August 12, 2021) (collectively with the Common Stock, the ‘Securities’) of ImmunoCellular Therapeutics, Ltd. (the 'Company') from listing and registration on the Exchange on October 29, 2018 pursuant to the provisions of Rule 12d2-2(b), because, in the opinion of the Exchange, the Common Stock is no longer suitable for continued listing and trading on the Exchange.

NYSE Regulation, Inc. (‘NYSE Regulation') reached its decision to initiate delisting proceedings pursuant to Section 1003 of the NYSE American Company Guide due to the abnormally low trading price of the Common Stock.

On October 16, 2018, NYSE Regulation determined that the Securities of the Company should be suspended immediately from trading, and directed the preparation and filing with the SEC of this application for the removal of the Securities from listing and registration on the Exchange. The Company was notified by phone and by letter on October 16, 2018.

Pursuant to the above authorization, a press release regarding the proposed delisting was issued and posted on the Exchange’s website on October 16, 2018. Trading in the Securities were immediately suspended on October 16, 2018.

The Company had a right to appeal the determination to delist the Securities by a Committee of the Board of Directors of the Exchange, provided that it filed a written request for such a review with the Secretary of the Exchange within seven business days of receiving notice of the delisting determination. The Company disclosed in its press release dated October 17, 2018 that it does not intend to file such request within the specified time period. Consequently, all conditions precedent under SEC Rule 12d2-2(b) to the filing of this application have been satisfied.